GRCE
Grace Therapeutics, Inc.
NASDAQ: GRCE · HEALTHCARE · BIOTECHNOLOGY
$2.10
+0.00% today
Updated 2026-04-29
Market cap
$33.42M
P/E ratio
—
P/S ratio
197.75x
EPS (TTM)
$-0.31
Dividend yield
—
52W range
$2 – $5
Volume
0.8M
Grace Therapeutics, Inc. (GRCE) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-1.90M | $-1.91M | $-5.65M | $-2.49M | $-6.12M | $-5.75M | $-4.85M | $-9.69M | $-24.79M | $-22.95M | $-14.32M | $-17.23M | $-15.91M | $-12.33M | $-14.90M |
| Capital expenditures | $15356.00 | $21575.00 | $0.00 | $100676.00 | $133562.00 | $68735.00 | $271564.00 | $352328.00 | $534000.00 | $319000.00 | $69000.00 | $0.00 | $17000.00 | $22000.00 | $0.00 |
| Depreciation | $8624.00 | $685262.00 | $671763.00 | $649601.00 | $1.59M | $1.87M | $1.77M | $2.07M | $2.33M | $2.32M | $924000.00 | $0.00 | $124000.00 | $11000.00 | $7000.00 |
| Stock-based comp | — | $185147.00 | $1.33M | $1.87M | $3.09M | $1.24M | $228025.00 | $719368.00 | $777000.00 | $1.95M | $1.17M | $1.34M | $1.81M | $913000.00 | $730000.00 |
| Free cash flow | $-1.92M | $-1.94M | $-5.65M | $-2.59M | $-6.25M | $-5.82M | $-5.12M | $-10.05M | $-25.32M | $-23.27M | $-14.39M | $-17.23M | $-15.93M | $-12.36M | $-14.90M |
| Investing cash flow | $1.90M | $-2.57M | $-3.01M | $1.85M | $-17.48M | $6.10M | $6.07M | $-318256.00 | $-9.44M | $8.14M | $-9.86M | $-3.52M | $13.15M | $104000.00 | — |
| Financing cash flow | $77400.00 | $4.40M | $9.94M | $221530.00 | $22.44M | $36765.00 | $-2213.00 | $8.83M | $45.69M | $13.18M | $59.49M | $0.00 | $304000.00 | $7.36M | $14.03M |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |